Navigation Links
ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call
Date:7/24/2008

PLYMOUTH, Minn., July 24 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq: EVVV) today announced a revised date to report its 2008 second quarter and year-to-date financial results. ev3 will now report its 2008 second quarter and year-to-date financial results on Monday, July 28, 2008, after regular market trading hours.

The company will host a conference call and webcast at 7:30 a.m. Central Time (8:30 a.m. Eastern Time) on Tuesday, July 29, 2008. ev3 management will review its second quarter operating results and future outlook, followed by a question and answer session.

The conference call will be available to interested parties through a live audio webcast at http://ir.ev3.net, where it will be archived and accessible for approximately 90 days. The live dial-in number for the call is 888-679-8033 (U.S.) or 617-213-4846 (International). The participant passcode is 64950600.

If you do not have access to the Internet and want to listen to an audio replay of the conference call, dial 888-286-8010 (U.S.) or 617-801-6888 (International) and enter passcode 10431647. The audio replay will be available beginning at 9:30 a.m. Central Time on Tuesday, July 29, 2008 until Tuesday, August 5, 2008.

About ev3 Inc.

Since its founding in 2000, ev3 has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of lower extremity vascular and neurovascular diseases. ev3's products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today -- peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, thrombectomy catheters and occlusion balloons. More information about the company
'/>"/>

SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. The Connecticut Hospice, Inc. Announces the Arrival of Six Nurse Scholars From The Henrietta Szold-Hadassah-Hebrew University School of Nursing
2. ThermoGenesis Announces 10 New BioArchive(R) System Distributors
3. Tepha Announces Appointment of John Hartnett as Executive Vice President and Chief Operating Officer
4. BD Announces Results for Third Fiscal Quarter
5. Gerbig Engineering Announces Availability of Cleanroom Utility Panel
6. The Palomino Group Announces Launch of Meeting Support Services Business Unit
7. Misys Announces Preliminary Results for the Year Ended 31 May 2008
8. Cardiome Announces Preferred Share Financing
9. Mercy Health Plans Announces New Name for Their Medicare Advantage Plans: Mercy Medicare Advantage
10. American Heart Associations Announces Call for Entries for Howard L. Lewis Achievement Award
11. The Risk Management and Patient Safety Institute Announces 2008/2009 Annual Risk Management Conference, Dates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...ug. 29 /PRNewswire-FirstCall/ -- Landauer, Inc. (N...ors declared a regular,quarterly cash dividend of ...008. The dividend will be paid on October 3, 2008,... About Landauer, Landauer is the leading provide... and environmental radiation exposure. For more th...
(Date:8/29/2008)...fic obligation reduced from $250 to $19 million, ...oston Scientific,Corporation (NYSE: BSX ) today a... Texas found two patents of Medtronic, Inc. (NYSE:...ng the prosecution of the patents,before the Unite... previously found that certain Boston Scientific b...
(Date:8/29/2008)... Dr. Milton Owens and the Coastal Center for O...ia to provide protection for cash paying patients ...ic community is benefiting. , .... Milton Owens and the Coastal Center for Obesity ...rovide protection for cash paying patients in the ...
(Date:8/29/2008)... Trusted life science software provider allows...ngage via GSA. , Reston, ...erging software engineering firm dedicated to the...ral Services Administration (GSA) Contract. The GS...h the ability to conveniently engage 5AM Solutions...
Breaking Medicine News(10 mins):Health News:Court Rejects Two Medtronic Patents 2Health News:Court Rejects Two Medtronic Patents 3Health News:Coastal Center for Obesity Offers Hispanics Weight Loss Surgery with a Warranty 2Health News:Federal and State Agencies Have Easier Access to 5AM Solutions' Award-Winning Software Services 2
... Citys smoking rate has shown a decline, thanks to...okers to kick the habit. The statistics in the 200...0%, in comparison to 2002 figures. Over the past y...rom 22.5% to 19.9%) and among Hispanics (from 20.2...
... molecular on switch triggers gene activity that ...abilities to glucose production in the liver was ...earch hospital . The on switch, a protein called...ule that binds to a section of DNA near a gene and...
... in Tamil Nadu, who allegedly tried to get his 15-... to perform a caesarean operation , today said the... him. Dr. Murugan rubbished the media reports that...n Dhileepan Raj, a tenth standard student, operati...
...stoma typically occurs as a solid tumor in the ab...veloping in the network of the body's sympathetic ... rare, but among them, neuroblastoma is a special ...t of all childhood cancers, but 15 percent of chil...
Other Medicine News:Health News:New York Records Decline in Smoking Rate 2Health News:Research Studies on Molecular Switches of Gene 2Health News:The Bottleneck in Neuroblastoma 2
(Date:8/27/2008)...in Parts of Bucks, Delaware, Montgomery,Philadelp...e-USNewswire/ -- After encouraging,results followi...tment of,Environmental Protection will continue it...st the mosquito-borne West Nile virus., Targeted ....m. and,midnight in portions of Bucks, Delaware, M...
(Date:8/27/2008)..., melphalan and prednisone arm demonstrated a, si... complete response -, CAMBRIDGE, Mass., Aug. 27 /...pany today announced the publication of results fr... trial in this week,s edition of the,New England J...nt survival,benefit and a 30 percent complete remi...
(Date:8/27/2008)...7 /-, - Oralair(R) Grasses...acodynamic Study Conducted in an Allergen Challeng... positive results of a new study,conducted in an A...alair(R) Grasses included 86 adult patients expose...nt durations: 1 week, 1 month,2 and 4 months with...
(Date:8/27/2008)...rom BLISS-52 trial, expected by mid-2009 - - Data...fall 2009 -, ROCKVILLE, Md., Aug. 27 /PRNewswire-... HGSI ) today announced it has completed enrollme...wo pivotal Phase 3,randomized clinical trials of L... systemic lupus erythematosus (SLE). Belimumab is ...
Breaking Medicine Technology:DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 2DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Hiemstra Approved to Manufacture Medical Devices in New CER 9345 1Hiemstra Approved to Manufacture Medical Devices in New CER 9345 2TeamStaff Receives Nasdaq Determination Letter 9340 1TeamStaff Receives Nasdaq Determination Letter 9340 2TeamStaff Receives Nasdaq Determination Letter 9340 3Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Cli 1178 1Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Cli 1178 2Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Cli 1178 3Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Cli 1178 4Chromosome Abnormalities Raise Risk for Autism 9333 1Chromosome Abnormalities Raise Risk for Autism 9333 2Chromosome Abnormalities Raise Risk for Autism 9333 3Chromosome Abnormalities Raise Risk for Autism 9333 4
...Family History of ESRD Are at High,Risk , ,WASHIN...f U.S.,adults have a family history of end-stage r...to be at increased risk of developing,kidney disea...l of,the American Society of Nephrology. , "A fami...frican-Americans, who are also at substantially hi...
...ibody significantly reduced the number of,new or e...bmitted,for presentation at upcoming medical meeti...12, 2007,/PRNewswire-FirstCall/ -- Biogen Idec, In...hat the ongoing CHOICE trial, a Phase 2,randomize...zumab,met its primary endpoint in relapsing multi...
Other Medicine Technology:Nearly 1 in 10 Americans Has A Relative With Kidney Failure 2Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 2Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 3Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 4Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 5
...gnostics is a leading provider of immunofluorescen... that includes kits for autoimmune diseases, infec...onjugates and components. Our Impact IFA Test Syst...it sizes to choose from. Kit components include su...
...gnostics is a leading provider of immunofluorescen... that includes kits for autoimmune diseases, infec...onjugates and components. Our Impact IFA Test Syst...it sizes to choose from. Kit components include su...
...gnostics is a leading provider of immunofluorescen... that includes kits for autoimmune diseases, infec...onjugates and components. Our Impact IFA Test Syst...it sizes to choose from. Kit components include su...
...ELISA products make us a leader in this field. Wit...into the busy laboratory, our Infectious Disease E...n-to-run consistency. Our Infectious Disease ELISA...e range of serological assays including ToRCH, EBV...
Medicine Products: